Aggregation of hyperphosphorylated tau is a major hallmark of many neurodegenerative diseases, including Alzheimer's disease. In vivo imaging with positron emission tomography (PET) may offer important insights in pathophysiological mechanisms, diagnosis and disease progression. We describe different strategies for quantification of 18 F-AV1451 (T807) tau binding, including models with blood sampling and non-invasive alternatives.
INTRODUCTION
Alzheimer's disease is a neurodegenerative disorder with progressing dementia, neuropathologically characterized by amyloid-beta deposition in the form of senile plaques and aggregation of hyperphosphorylated tau as neurofibrillary tangles, leading to neuronal dysfunction and cell death (1, 2) . The formation of amyloid-beta plaques may already occur even decades before symptom onset, whereas tau deposition is more closely related to the disease duration and severity (3, 4) , making it a potentially important marker for monitoring disease progression and treatment strategies (5) . Furthermore, tau aggregation is implicated in a series of other neurodegenerative diseases such as cortico basal syndrome, progressive supranuclear palsy and frontotemporal dementia.
Although biomarkers obtained from cerebrospinal fluid demonstrate great clinical utility (6) , the procedure does not yield information about the spatial distribution of tau pathology in the brain. Hence, robust non-invasive imaging markers would offer an important advancement for diagnosis and monitoring of disease progression. Several PET radioligands have been developed with high sensitivity for tau (1, 7) (supplement). Among those, 18 F-AV1451 shows promising characteristics for tau quantification. The radioligand exhibits a more than 25-fold higher sensitivity for tau than amyloid beta (8) , a high gray to white matter contrast (9) and negligible non-specific binding to several other targets such as monoamine oxidase A and B (8) .
Further, radioactive metabolites of 18 F-AV1451 are unlikely to pass the blood brain barrier (8) and little tracer uptake in the bone has been reported (9) . Initial human studies have demonstrated increased binding in patients with AD and mild cognitive impairment when compared to healthy controls (10) . Although quantification with reference region models and ratio methods was recently reported (11) , validation with arterial blood sampling and scan durations > 100 min is still missing.
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The aim of this work was to establish an optimal quantification procedure for tau binding with 18 F-AV1451, both for research related and clinical purposes. This included the identification of an optimal modeling strategy with arterial blood sampling as gold standard, the assessment of non-invasive alternatives and simplified ratio methods. We further evaluated different scan time intervals between 40 and 180 min when using standard uptake values (SUV) and ratios (SUVR) for potential clinical applicability when separating AD patients from controls.
METHODS

Subjects
Fifteen subjects participated in this study. These included 4 healthy controls (HC, mean age±sd = 75.0±3.8 years, 1 female), 6 patients with Alzheimer's disease (AD, 64.8±14.7 years, 2 female), 2 patients with cortico basal syndrome (CBS, 66.5±0.7 years, 2 females) and 3 patients with progressive supranuclear palsy (PSP, 74.3±5.8 years, 0 females). See supplement for clinical evaluation and exclusion criteria. All subjects signed a written informed consent after detailed explanation of the study protocol. The procedures were approved by the Ethical Review Board of Lund University (2014-233) and the Swedish Medical Products Agency. All procedures were carried out according to the Declaration of Helsinki.
Positron emission tomography
Subjects underwent a 180min PET examination with 18 F-AV1451 on a GE Discovery 690 PET/CT (General Electric Medical Systems, Milwaukee, WI, USA) scanner at Skåne University Hospital, Lund, Sweden. See supplement for radiolabeling and acquisition details. Mean i.v.
injected dose was 371.1±14.1 MBq (5.58±1.43 MBq/kg body weight) and the radioligand was administered as a bolus over 40s.
Blood sampling
by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from A cannula was inserted into the radial artery, after which arterial blood samples were obtained manually (supplement). Radioactive metabolites were determined using high performance liquid chromatography (supplement). The parent fraction was fitted with a Hill function (12) , multiplied with the plasma curve which was finally fitted with a tri-exponential function from the peak onwards to obtain the arterial input function. The individual delay of the radioligand between the sampling site (A. radialis) and the brain was estimated by modeling a whole-brain time activity curve (13) .
Data processing
Coregistration, spatial normalization and segmentation were performed with the Advanced Neuroimaging Tools (ANT, http://stnava.github.io/ANTs/, supplement).
Regions of interest
Regions of interest were derived from the Harvard-Oxford atlas and the probabilistic cerebellar atlas provided in FSL (http://fsl.fmrib.ox.ac.uk/fsl/). These were frontal, temporal, parietal, occipital and cingulate cortices, thalamus, putamen, caudate, hippocampus and the cerebellar gray matter excluding vermis (and hence also excluding the dentate nucleus, potentially showing increased binding in PSP patients, supplement).
Quantitative analysis
To estimate tau binding several quantification strategies were employed ( Table 1 ). The optimal model was identified based on the structure of residuals (14) , goodness of fit (Akaike information criterion) and variance of the outcome parameter (% standard error, MarquartLevenberg optimization calculated in PMOD). Using the arterial input function, we applied one-, two-or three-tissue compartment models (TCM) with and without K 1 /k 2 coupled across regions as well as the Logan plot (15) . The primary outcome parameter was the total volume of by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from distribution (V T ) for 1TCM and Logan plot as well as the specific volume of distribution or binding potential (V S = BP P ) for 2TCM and 3TCM (16) . Assuming that the cerebellum contains only nondisplaceable binding (discussion and (17)), we also computed V S = V T -V T_cerebellum , the distribution volume ratio DVR = V T / V T_cerebellum and BP ND = (V T -V T_cerebellum ) / V T_cerebellum from the Logan plot. These metrics served for comparison with simplified methods (Table 2 ). The cerebral blood volume component was fixed to 5% for all models and brain regions.
Reference region models were applied including the simplified reference tissue model 2 (SRTM2) (18) and the Logan reference plot (19) , with the cerebellum as reference, yielding BP ND and DVR = BP ND + 1 as outcome measure, respectively. For the Logan reference plot, k 2 ' was estimated with the SRTM2 in temporal and cerebellar cortices. For direct comparison, the calculations with the SRTM2 were additionally carried out with the same k 2 ' fixed for all regions. 
Statistics
To assess the similarity between the optimal 180 min arterial-based model and simplified methods (reference region models, ratio methods and SUV with shortened scan time), linear regression analysis was computed across all brain regions and subjects. Here, outcome parameters from simplified methods were compared with the correspondingly transformed by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from outcome from the arterial-based Logan plot; e.g., SUVR compared to DVR = V T /V T_Cereb from arterial-based Logan plot, etc (Table 2 ). This yields R 2 as a value of reproducibility as well as slope and intercept indicating constant bias and scaling errors, respectively. For clinical applicability, the difference between AD patients and controls was calculated using independent samples t-tests, in order to normalize for differences in the variance for different outcome measures. Due to the low sample size this comparison was not carried out for CBS and PSP patients.
RESULTS
Blood data
Whole blood and plasma activities showed rapid clearance of the radioligand from plasma (Fig. 1a) . Plasma-to-whole blood ratios approached 1 after 20 min and increased slowly throughout the measurement (Fig. 1b) . Metabolism occurred at a moderate pace, with approximately 50% parent compound being available after 30 min (Fig. 1b) . In line with previous studies (8, 20) , a single radioactive metabolite was observed with high performance liquid chromatography (presumably 18 F -), which was more polar than the parent compound (retention times, 3.7 and 7.5min, Figs. 1c and 1d) and was thus considered unlikely to pass the blood brain barrier.
Arterial-based models
The delay of the input function was -0.8±2.9 s (range = -6.7…3.4 s). None of the compartment models adequately described the data for all subjects or regions (Fig. 2,   Supplemental Figs. 1 and 3 ). In contrast, the Logan plot showed excellent fits ( 
Ratio methods
SUVR showed strong agreement with the arterial-based Logan plot (R 2 = 0.88-0.94, Table 2 ). Although SUVR correlations were similar for all intervals > 80 min, 100-120 min performed best, whereas 80-100 min may represent a reasonable compromise between duration and accuracy. For SUV, only moderate agreement with the arterial-based Logan V T was obtained (R 2 = 0.69-0.82) with highest correlations occurring for 120-140 min. Figure 3 shows time activity curves normalized by injected dose (SUV), by plasma activity and by the cerebellum (SUVR). Interestingly, the putamen showed rather different kinetics than any other brain region, especially for healthy controls.
Group differences in 18 F-AV1451 binding
Compared to cerebellum, average binding in HC was similar for cortical regions and the hippocampus, but higher for subcortical areas. Logan V T was markedly higher for AD patients than HC across all cortical regions, whereas for PSP and CBS patients Logan V T was slightly lower for all regions (Fig. 4a) . Conversely, Logan V T in the cerebellum was lower in all patient groups when compared to HC (16.5%). This seems to be attributable to a minor extent to by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from differences in gray matter volume, which was 8.1% lower in patients. Correcting for the differences in cerebellar V T , Logan V S showed more pronounced differences between AD and HC including the hippocampus and slightly increased binding for CBS patients in temporal, parietal and occipital cortices (Fig. 4b) . Similarly, SUVR calculated for 80-100 min, resulted in 1.6 to 2.2-fold higher binding for AD and up to 1.3-fold increased binding for CBS in the cortex (Fig. 4c) . Differences between PSP and HC were generally low for Logan V S and SUVR.
Assessing group differences between AD patients and HC in cortical regions showed best separation for Logan V S and SUVR 80-100 min (Fig. 5) . The SRTM2 and Logan reference region models performed almost equally well, whereas SUV methods only yielded differences for selected brain regions.
Voxel-wise quantification confirmed increased binding in AD for Logan plot V T as well as
Logan reference plot DVR and SUVR, but only to a lesser extent for SUV (Fig. 6 ).
DISCUSSION
We evaluated various strategies for quantification of tau binding with the radioligand 18 F-AV1451. Tissue compartment models did not describe the kinetics appropriately, whereas the Logan plot yielded excellent fits and low parameter variance. Reference region models as well as SUVR gave strong agreement with the Logan plot.
We observed that none of the compartment models were able to describe the kinetics of 18 F-AV1451 with 33-53% modeling failures in cortex and 80% in subcortical regions. Still, it is possible that more complex compartmental configurations may yield better fits, however, such approaches often come at the expense of increased parameter variance. Although no indications were found that parameter coupling alone or metabolites would explain the lack of compartment model fits, future studies are required to clarify this issue. We propose binding estimates from the Logan plot as the currently best arterial-based solution. In line, usage of graphical analyses has been suggested for the quantification of 11 C-PBB3 tau binding (21) and 11 C-PiB amyloid binding (22). For 11 C-PBB3, the lack of adequate fits with compartment modeling may be ascribed to radiometabolites entering the brain (21). Conversely, good 2TCM fits were obtained for (S)-18 F-THK5117 but the corresponding outcome parameters could not be robustly identified, hence, simplified methods were also evaluated with reference to the arterialbased Logan plot (23).
A prerequisite for calculation of Logan plot V S is that a reference region is available, as for the above mentioned ligands (21, 22). Here, the cerebellar gray matter was assumed to be devoid of target protein and hence represent only non-specific binding. Although a blocking study would be required to validate the assumption in vivo (24, 25), strong support comes from various findings. First, no specific AV1451 binding was observed in the cerebellum post-mortem across a wide range of clinical populations and methods (17, 26) . Furthermore, we add in vivo data, showing that cerebellar kinetics were equal to those of the cortical areas in healthy controls, all presumably devoid of PHF tau. Nevertheless, average cerebellar V T obtained from the arterial-based Logan plot was higher in controls than patient groups, which is unlikely to represent specific tau binding as for reasons above. Rather, the increased cerebellar V T might be attributable to physiological variation and/or potential off-target binding. Usage of V T as outcome parameter is however not sensitive to detect whether group differences are attributable to changes in V S or V ND . Assuming that V ND is constant across the brain it is informative to account for such differences by deriving V S or DVR. Although various other secondary binding sites have been excluded (8) , it seems that 18 F-AV1451 binds to some extent to factors present in neuromelanin-and melanin-containing cells (17) . The potential off-target binding may also be reflected in the higher in vivo retention in the basal ganglia (10, 11, 17, 27) , which was recently linked to iron content (28). This was particularly prominent in the healthy control group, with the putamen showing higher SUV and SUVR than any other brain region. Further, in AD patients by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from kinetics of the putamen were markedly different from cortical areas know to be affected by tau aggregates. These findings indicate that 18 F-AV1451 binding in the putamen is not related to PHF, but caused by yet unknown mechanisms potentially involving a secondary binding site. On the other hand, the present results of cortical 18 F-AV1451 binding in AD reflects autoradiography (17) and human imaging data (10) (supplement).
The results from this work may also have clinical implications. Simplified analyses showed strong agreement of reference region based BP ND and DVR as well as SUVR when compared to the arterial-based Logan plot. As expected, longer scan times show better agreement, but strong correlations were already observed for 100 min (R 2 > 0.9), indicating that reliable results can be obtained with shorter scans. For SUVR, the interval 80-100 min seems to provide a robust simplification, which can be realized by a 20 min static scan without blood sampling. This protocol may offer examination of several consecutive patients with a single synthesis followed by simple analysis of calculating ratios. Accordingly, similar differences between AD patients and controls (t-values) for the ratio methods and arterial-based Logan plot were observed. Despite the steady increase of SUVR across time in AD patients, the t-values did not increase for longer time intervals, since also the variance in AD increased. Hence, the increase in absolute SUVR seems only to affect slope and intercept when compared to the arterial-based Logan plot. Still, a larger patient cohort is required to assess whether the SUVR obtained from 80-100 min is sufficient for clinical evaluation, especially as a prognostic marker.
Finally, SUV cannot be recommended for clinical evaluation due to high unexplained variance when compared with the arterial-based Logan plot. This was reflected in the underestimated differences between AD patients and controls for various brain regions.
One limitation of this study is the low sample size. However, as the pharmacokinetic characteristics were rather uniform within groups, the data at hand seems to be representative
for a methodological evaluation. Furthermore, we were not aiming to infer statistical differences between groups but rather to identify optimal quantification strategies. The sample size is similar to previous methodological work, which focused on quantitative characterization of novel radioligands (12, 22, 24) . Another aspect is that no partial volume correction was carried out.
Tissue loss may indeed alter the absolute values of the outcome parameters, but since tracer kinetics are not affected, the data seems representative for the evaluation of a quantitative description.
CONCLUSIONS
The Logan plot is the method of choice for input function-based quantification of 18 F-AV1451 binding. Using cerebellum as reference region, simplified techniques can be employed, potentially offering clinical applicability with a static scan at 80-100 min and ratio methods.
Compared to healthy controls, these approaches showed higher in vivo binding for AD and to some extent also for CBS patients.
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SUPPLEMENTAL INTRODUCTION
Several positron emission tomography (PET) radioligands have been developed, which show high sensitivity for tau over amyloid beta (1, 2) . These include the family of THK-compounds (3), 11 C-PBB3 as well as 18 F-T808 and 18 F-AV1451 (formerly known as T807). Of those, only 11 C-PBB3 (4) and (S)-18 F-THK5117 (5) have yet undergone full quantitative description. Although robust quantification was obtained both with an arterial-based model and simplified ratio methods, 11 C-PBB3 exhibits a radioactive metabolite that crosses the blood brain barrier, making full quantification challenging. In addition, labeling with carbon-11 may complicate clinical applicability due to the short half-life, which impedes shipping and limits each synthesis to few scans. On the other hand, (S)-18 F-THK5117 showed promising results, with strong agreement between arterial-based and non-invasive models for PET scans as short as 60min (5) . However, the radioligand exhibits high white matter uptake and less signal to noise ratio as compared to other THK compounds (3). Although 18 F-T808 does not include these issues, the radioligand is subject to substantial defluorination (6) . The resulting bone uptake may in turn complicate exact quantification of nearby cortical areas due to spill over and partial volume effects occurring from limited PET resolution (7) .
SUPPLEMENTAL METHODS
Subjects
All patients underwent a clinical and neurological exam and were assessed using the Hoehn and (9), and were further assessed using the PSP rating scale and the Unified Parkinson's Disease Rating Scale (UPDRS)-III. CBS patients were diagnosed in accordance with clinicopathologic guidelines (10).
Healthy controls had no previous neurologic or psychiatric disorders. Exclusion criteria were current alcohol or drug abuse, other major or recurrent neurological or psychiatric disorders, inability to undergo magnetic resonance imaging (MRI) and severe renal, hepatic impairment or significant infectious disease.
Radiolabeling of [18F]AV1451
[ 18 
Positron emission tomography
To minimize head motion during the acquisition, the subject's head was strapped to a dedicated head holder. List mode data was acquired from 0-60min, 80-140 min and 160-180 min post injection. For attenuation correction, a separate low dose CT was obtained before each scan session. To reduce motion artifacts, the non-attenuation correction PET images were visually inspected and, if required, manually aligned to the CT image, after which the corresponding sinograms were aligned accordingly. Following this alignment step, the PET images were reconstructed again with attenuation correction, using an iterative Vue Point HD algorithm (6 subsets, 18 iterations, 3 mm filter, no time-of-flight correction). These parameter settings were established using phantom measurements and preliminary data analysis. The acquisitions were reconstructed into frames of 12x10 s, 6x20 s, 6x30 s, 3x60 s, 5x120 s and 8x300 s (0-60 min) as well as 12x300 s (80-140 min) and 4x300 s (160-180 min). The resolution of the PET scanner is 4.7 mm transverse and 4.74 mm axial full-width at half-maximum 1 cm next to the center of the field of view (11) . Plasma was separated by centrifugation and radioactivity levels in both whole-blood and plasma samples (3 mL each) were measured in a ɣ-counter (PerkinElmer 1480 Wizard).
Determination of radioactive metabolites was carried out for 10 mL samples at 5, 15, 30, 45, 60, 90, 120 and 180 min using high performance liquid chromatography. Plasma was obtained by 6 min centrifugation at 4400 rpm and 4 °C. Plasma proteins were precipitated by adding acetonitrile (2.5 mL) to the plasma (2.5 mL). The resulting mixture was centrifuged at 4400 rpm for 6 min. Two mL of the supernatant was injected into a HPLC to separate the parent tracer from its radioactive metabolites (pump, injector and UV-detector: Ultimate 3000, Dionex; BGO radioactivity detector: Bioscan). The sample was injected on a Chromolith®SemiPrep, RP-18e 100-10 mm column, 100 x 4.6 mm. The tracer and its metabolite were eluted with 0.1 % TFA in 
Magnetic resonance imaging
Structural images were obtained with a T1-weighted magnetization-prepared rapid gradient echo sequence using a 3T Siemens Skyra scanner (Erlangen, Germany). Sequence parameters were TE/TR = 2.54/1900ms, acquiring 176 slices with 1mm isotropic resolution. Structural images were used for coregistration with PET images and transformation of regions of interest to individual space.
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Data processing
PET images were corrected for head motion by coregistration of each frame to the first frame within that data set, using a 6 parameter rigid transformation. Delineation of brain regions was carried out automatically as follows. After brain extraction of the structural MR images, the summed PET images of each session were separately coregistered to the MRI. The structural MR image was then spatially normalized to the MNI152 structural template (Montreal Neurological Institute) and segmented into gray and white matter as well as cerebrospinal fluid.
Cortical template brain regions (see below for details) were then masked with a 50% gray matter mask in order to reduce spill over from non-gray matter areas, whereas subcortical regions were masked with a tissue mask (consisting of gray and white matter). Using the inverse transformation matrices, the masked brain regions were then warped into PET space, and projected onto the dynamic PET image to obtain regional time activity curves (TACs).
Regions of interest (ROI)
The frontal ROI included the frontal pole, the superior, middle and inferior (pars triangularis, pars opercularis) frontal gyrus. The temporal region contained the superior (anterior and posterior divisions), middle and inferior temporal gyrus (anterior, posterior and temporooccipital parts).
The parietal ROI included the superior parietal lobe, the supramarginal (anterior and posterior) and the angular gyrus. The occipital region contained lateral occipital (inferior and superior divisions) and the intracalcarine cortices. The cingulate ROI comprised the anterior and posterior cingulate gyrus. If an ROI contained several subparts, TACs were generated from these multiple ROIs as an average weighted by size of the subparts. Regions were averaged for left and right hemisphere, except for CBS patients, where only the affected hemisphere was included.
SUPPLEMENTAL RESULTS
Arterial-based models
Compartmental modeling results were similar cortex and hippocampus as well as across the remaining subcortical regions independent of the configuration. The 1TCM did not provide acceptable fits throughout as illustrated by the residuals (Supplemental Fig. 1a ) and highest Akaike information criterion values (Supplemental Fig. 2a) . For cortical regions, the 2TCM showed poor fits for more than 1 ROI in 8 subjects ( Fig. 2a; Supplemental Fig. 1b) . Although coupling of K 1 /k 2 decreased the variance of outcome parameters (Supplemental Fig. 2b ), model fits were even worse for 3 subjects (all AD patients, Supplemental Fig. 1c) . Adding a third tissue compartment to the model, improved the model fits in these 3 subjects (Fig. 2b ) with all other subjects showing identical fits (Supplemental Fig. 1d-e) . As expected, parameter variability was poor for the unconstrained 3TCM, whereas coupling K 1 /k 2 improved this issue.
For subcortical regions, the 2TCM did not reach satisfactory fits in 12 subjects, which did not improve with a 3TCM or when coupling K 1 /k 2 (Supplemental Fig. 2a) . Regarding the cerebellar gray matter, 2TCM fits were not acceptable for 7 subjects. This only improved for 1 subject (AD) when using the 3TCM, but coupling K 1 /k 2 had no effect.
Using spectral analysis, shortened scan time of 60 or 120 min, weighting data by frame duration (data not shown) or ROI refinement to smaller subregions (Supplemental Fig. 3) did not improve the model fits. As expected, the V T as outcome parameter showed considerably lower standard errors, however, this does not change the issue of generally poor fits for compartment models. by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from
SUPPLEMENTAL DISCUSSION
We observed slightly increased cortical binding in CBS but not PSP patients. This fits with postmortem data as both groups exhibit the straight filament (12, 13) and AV1451 binds only to a lesser extent to this isoform (14) . The remaining in vivo difference observed here may thus be related to other characteristics, such as binding to astrocytic plaques (CBS) and tufted astrocytes (PSP) (12, 13) as well as no (PSP), intermediate (CBS) and strong binding to Nterminal tau parts (AD) (15) . On the other hand, the present results of 18 F-AV1451 binding in AD reflects autoradiography (14) and human imaging data (16) , where higher binding in parietal and occipital cortices is presumably attributable to PHF containing neurites in addition to PHF tangles (14, 17) . Notably, (S)-18 F-THK5117 showed a rather different topology with highest binding in the amygdala, temporal and frontal regions (5) , indicating that this compound may only bind to PHF tangles but not PHF containing neurites. The potential consequences of the regionally different binding between the ligands with respect to diagnosis and outcome still remain to be evaluated.
